INTRODUCTION {#s1}
============

Upper urinary tract urothelial carcinoma (UTUC) is a relatively rare malignancy, accounting for only 5--10% of urothelial carcinomas (UCs) \[[@R1]\]. Radical nephroureterectomy (RNU) with ipsilateral bladder cuff excision remains the standard treatment for patients with large, multifocal or high-grade tumors \[[@R1]\]. Despite definitive surgery, UTUC has high potential for local and distant recurrence, especially in patients with advanced disease \[[@R2], [@R3]\].

The identification of new prognostic factors could help guide decisions regarding administration of adjuvant chemotherapy and selective enrolment into clinical trials of novel therapies. Tumor stage and grade have been documented as the major prognostic factors in patients with UTUC \[[@R1], [@R2]\]. In addition, tumor size, architecture, location and multiplicity as well as lymphovascular invasion (LVI) have been suggested as potential prognostic factors \[[@R1]\]. However, to date, the definite risk factors for recurrence and survival in patients who received RNU are still unclear.

Previous reports showed that demographic factors, such as age \[[@R3]\], gender \[[@R4]\], performance status \[[@R5]\], smoking status \[[@R6]\] obesity \[[@R7]\] and race \[[@R8]\] may have prognostic value in UTUC.

However, because of the rarity of the disease and the contradictory conclusions among previous studies, the prognostic significance of demographics has not been clearly established in UTUC. Our purpose was to assess the value of demographic data as prognostic factors for UTUC after RNU through a systematic review of the literature and meta-analysis of the available data.

RESULTS {#s2}
=======

Study population {#s2_1}
----------------

Table [1](#T1){ref-type="table"} shows individual data on the characteristics of the included studies and patient populations. We included 79 studies, comprising patients from Asia, North America, and Europe, with numbers of patients ranging from 24 to 9899. The studies were published between 1994 and 2014 and the patient recruitment periods ranged from 1986 to 2013. The median age ranged from 61 to 73 years and the median follow-up time was between 17.8 and 84 months. Only one was a prospective study \[[@R9]\]. Other pathologic characteristics of the eligible studies are reported in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

###### Study and patient characteristics of the eligible studies

  Study                       Year   Country       Recruitment period   No. of patients   Median age, range (years)   No. of sex (male/female)   Median follow-up, range (months)   No. of NACH   No. of ACH   No. of ART
  --------------------------- ------ ------------- -------------------- ----------------- --------------------------- -------------------------- ---------------------------------- ------------- ------------ ------------
  Park \[[@R11]\]             2004   Korea         1991--2001           86                59.5 (mean)                 81/5                       43.8, 5-140                        0             14           5
  Chen \[[@R12]\]             2005   Taiwan        1993--2003           111               70.5 (mean), 38-91          69/42                      49.3 (mean), 1-136                 NA            9            4
  Ataus \[[@R13]\]            2006   Turkey        1993--2003           24                61, 34-74                   19/5                       34.8 (mean), 5-97                  NA            NA           NA
  Chung \[[@R14]\]            2007   Taiwan        1996--2006           150               NA                          66/84                      47.5, 3-121                        NA            0            NA
  Koda \[[@R15]\]             2007   Japan         1995--2005           106               70.4 (mean)                 NA                         17.5, 1-97                         NA            25           NA
  Akao \[[@R16]\]             2008   Japan         1992--2005           90                71                          57/33                      42, 2-179                          NA            24           16
  Berger \[[@R17]\]           2008   USA           1997--2005           100               73, 53-97                   65/35                      84, 24-120                         NA            NA           NA
  Li \[[@R18]\]               2008   Taiwan        1990--2005           260               65,23-87                    125/135                    56, 12-181                         0             0            NA
  Soga \[[@R19]\]             2008   Japan         1986--2005           46                NA                          34/12                      NA                                 NA            24           NA
  Capitanio \[[@R20]\]        2009   multination   1987--2007           1249              27-97                       846/403                    NA                                 0             0            NA
  Chung \[[@R21]\]            2009   Taiwan        1996--2006           76                66 (mean), 41-93            38/38                      48, 15-88                          NA            0            NA
  Kamihira \[[@R22]\]         2009   Japan         1995--2005           1003              68.6 (mean), 27-92          718/285                    20, 1-122                          NA            181          NA
  Favaretto (I) \[[@R23]\]    2010   USA           1995--2008           274               NA                          NA                         NA                                 NA            NA           NA
  Favaretto (II) \[[@R24]\]   2010   USA           1995--2008           253               72, 64-77 (IQR)             159/94                     48                                 0             NA           NA
  Ishikawa \[[@R25]\]         2010   Japan         1990--2005           208               70, 39-90                   139/69                     44, 1-212                          0             0            0
  Kim \[[@R26]\]              2010   Korea         1986--2006           238               64.1 (mean), 25-91          164/74                     53.4, 3-240                        NA            NA           NA
  Kobayashi \[[@R27]\]        2010   Japan         2000--2004           221               72, 46-92                   153/68                     38.4, 0.8-92.2                     0             35           NA
  Pieras \[[@R28]\]           2010   Spain         1990--2006           79                67, 65-69 (95% CI)          62/17                      71, 59-84 (95% CI)                 NA            NA           NA
  Takaoka \[[@R29]\]          2010   Japan         1989--2007           60                64.7 (mean), 40-83          40/20                      51.3, 1.5-223.8                    0             28           NA
  Cho \[[@R30]\]              2011   Korea         1994--2009           87                62.2, 33-85                 64/23                      32, 1-131                          NA            19           5
  Hou \[[@R31]\]              2011   Taiwan        2003--2007           192               69.8 (mean), 43-89          79/113                     43.8 (mean), 3.8-84.8              NA            NA           NA
  Ku \[[@R32]\]               2011   Korea         1991--2006           181               63, 36-90                   142/39                     37.5, 1-174                        NA            48           NA
  Walton \[[@R33]\]           2011   multination   1987--2008           773               68, 61-75 (IQR)             533/240                    34, 15-65 (IQR)                    0             66           NA
  Ariane \[[@R34]\]           2012   France        1995--2010           609               69.8, 61.9-76               415/194                    27, 10-48                          0             NA           NA
  Chen \[[@R35]\]             2012   China         2007--2009           85                NA                          58/24                      28, 5-60                           NA            NA           NA
  Chromecki \[[@R36]\]        2012   multination   1987--2007           2492              69.2, 54.1-84.2 (IQR)       1681/811                   45, 0-101 (IQR)                    NA            247          NA
  Godfrey \[[@R37]\]          2012   USA           1990--2010           211               70 (mean)                   124/87                     27, 11-65.5 (IQR)                  NA            NA           NA
  Hirano \[[@R38]\]           2012   Japan         1995--2010           151               NA                          121/30                     24, 3-162                          NA            51           NA
  Kobayashi \[[@R39]\]        2012   Japan         2005--2009           288               71.4, 32-89                 197/91                     20.2, 3-61.6                       0             47           0
  Kuroda \[[@R40]\]           2012   Japan         1999--2010           121               68, 38-86                   92/29                      44.4 (mean), 3.5-144.5             0             29           NA
  Liang \[[@R41]\]            2012   Taiwan        1996--2004           340               68, 34-87                   182/158                    38, 1-176                          0             20           4
  Cho \[[@R42]\]              2013   Korea         1994--2009           78                61.1 (mean), 33-85          58/20                      34, 12-132                         0             NA           NA
  Ehdaie \[[@R43]\]           2013   USA           1995--2008           288               71, 37-90                   187/101                    4.02 yr, 0.03-14.65 yr             NA            NA           NA
  Elalouf \[[@R44]\]          2013   France        1998--2011           237               69.3, 60-76 (IQR)           161/76                     44, 24-79 (IQR)                    0             23           NA
  Fairey \[[@R45]\]           2013   Canada        1994--2009           849               NA                          542/307                    2.2 yr, 0.6-5 yr                   NA            94           NA
  Fujita \[[@R46]\]           2013   Japan         1999--2011           139               72, 48-90                   91/48                      27, 1-139                          11            23           NA
  Gunay \[[@R47]\]            2013   Turkey        1987--2009           101               60.5 (mean)                 85/16                      56.2 (mean)                        NA            NA           NA
  Hashimoto \[[@R48]\]        2013   Japan         1997--2010           84                68.8                        59/25                      NA                                 NA            NA           NA
  Ito \[[@R49]\]              2013   Japan         2005--2008           72                NA                          43/29                      24.9, 2.6-39.3                     0             14           NA
  Kim \[[@R50]\]              2013   Korea         2000--2013           65                60.4 (mean), 37-87          40/25                      34, 12-114                         NA            36           NA
  Kim \[[@R51]\]              2013   Korea         1990--2010           422               64, 29-86                   318/104                    44, 3-257                          NA            51           NA
  Kusuda \[[@R52]\]           2013   Japan         2000--2009           502               NA                          360/142                    39 (mean), 6-134.8                 NA            NA           NA
  Milojevic \[[@R53]\]        2013   Serbia        1999--2010           183               66 (mean), 36-88            102/81                     35, 1-154                          0             NA           NA
  Morizane \[[@R54]\]         2013   Japan         1995--2011           99                73, 44-86                   71/28                      37.9, 6.6-171.4                    NA            33           NA
  Rink \[[@R55]\]             2013   multination   1987--2007           864               70, 61-76 (IQR)             553/311                    50, 23-90 (IQR)                    0             63           0
  Sakano \[[@R56]\]           2013   Japan         1995--2009           536               71, 32-93                   370/166                    40.9, 3-200                        32            NA           NA
  Shimamoto \[[@R57]\]        2013   Japan         1983--2008           105               66.9, 42-88                 74/31                      53 (mean)                          7             59           NA
  Takahara \[[@R58]\]         2013   Japan         1996--2009           103               68.6 (mean), 62-75 (IQR)    71/32                      29, 14-63 (IQR)                    NA            12           NA
  Xylinas \[[@R59]\]          2013   France        1995--2010           482               69.2, 60-76 (IQR)           332/150                    39.5, 25-60 (IQR)                  0             59           NA
  Zhang \[[@R60]\]            2013   China         2000--2010           217               69, 62-81                   130/87                     52, 12-78 (IQR)                    0             NA           NA
  Aziz \[[@R61]\]             2014   Germany       1990--2012           265               NA                          169/96                     23, 9-48 (IQR)                     0             47           NA
  Bachir \[[@R62]\]           2014   Canada        1990--2010           644               NA                          NA                         24.5                               28            76           NA
  Cho \[[@R63]\]              2014   Korea         2004--2012           147               70, 44-84                   41/106                     33, 1-191                          0             95           NA
  Choo \[[@R64]\]             2014   Korea         2000--2011           319               NA                          253/66                     NA                                 6             85           NA
  Ehdaie \[[@R65]\]           2014   USA           1995--2008           253               72, 63-77 (IQR)             158/95                     NA                                 0             0            NA
  Fang \[[@R66]\]             2014   China         2000--2010           438               66, 20-88                   187/251                    45, 12-144                         0             NA           NA
  Fradet \[[@R67]\]           2014   Canada        1990--2010           743               69.7 (mean)                 438/304                    24.8, 7.7-56.8 (IQR)               0             73           NA
  Fujita \[[@R68]\]           2014   Japan         1998--2012           226               70, 37-90                   153/73                     41, 1-164                          8             44           NA
  Gandaglia \[[@R69]\]        2014   USA           1988--2009           9899              73, 22-99                   5823/4076                  98, 0-263                          NA            NA           NA
  Ichimura \[[@R70]\]         2014   Japan         1996--2012           171               NA                          119/52                     56, 25-86 (IQR)                    0             NA           NA
  Ishioka (I) \[[@R71]\]      2014   Japan         1995--2010           1014              70, 62-79 (IQR)             718/296                    38, 16-73 (IQR)                    NA            155          NA
  Ishioka (II) \[[@R72]\]     2014   Japan         1995--2010           754               69, 62-75 (IQR)             526/228                    41, 18-75 (IQR)                    NA            NA           NA
  Ito \[[@R73]\]              2014   Japan         1999--2012           70                NA                          47/23                      29.2, 1-157                        NA            9            NA
  Kitamura \[[@R74]\]         2014   Japan         1995--2010           110               NA                          NA                         60, 6-192                          NA            NA           NA
  Kondo \[[@R75]\]            2014   Japan         1988--2013           180               NA                          128/52                     NA                                 NA            NA           NA
  Lee \[[@R76]\]              2014   Taiwan        2004--2010           250               NA                          108/142                    41                                 NA            NA           NA
  Liu (I) \[[@R77]\]          2014   China         1998--2009           230               NA                          179/51                     67, 34-170                         0             57           NA
  Liu (II) \[[@R78]\]         2014   China         2002--2010           212               66.5, 31-84                 123/89                     39, 7-78                           0             8            NA
  Ou \[[@R79]\]               2014   Taiwan        2003--2011           61                NA                          34/27                      39.7, 12-96                        0             0            0
  Park \[[@R80]\]             2014   Korea         1991--2010           392               64, 29-86                   299/93                     47.6, 2-257                        0             60           NA
  Sasaki \[[@R81]\]           2014   Japan         1996--2012           171               NA                          119/52                     NA                                 0             NA           NA
  Shirotake \[[@R82]\]        2014   Japan         1993--2011           873               70, 63-77 (IQR)             608/231                    32, 16-62 (IQR)                    0             129          NA
  Sung (I) \[[@R83]\]         2014   Korea         1994--2011           410               64, 55-72 (IQR)             312/98                     40.2, 33-66.1 (IQR)                NA            91           NA
  Sung (II) \[[@R84]\]        2014   Korea         1994--2010           386               NA                          293/93                     39, 21.1-70.6 (IQR)                NA            NA           NA
  Tanaka \[[@R85]\]           2014   Japan         1994--2010           474               69, 61-76 (IQR)             346/128                    35, 17-68 (IQR)                    0             78           NA
  Xylinas (I) \[[@R86]\]      2014   multination   1987--2007           519               70, 61-76 (IQR)             330/189                    37, 19-73 (IQR)                    0             53           0
  Xylinas (II) \[[@R87]\]     2014   multination   1987--2007           2681              68.4, 54-84                 1808/873                   57.5, 1-271                        0             264          NA
  Yafi \[[@R88]\]             2014   Canada        1995--2010           1029              70, 62-77 (IQR)             195/113                    17.8, 5.5-46.8                     NA            36           NA
  Zou \[[@R89]\]              2014   China         1999--2013           122               64, 35-80                   87/35                      53, 3-159                          NA            NA           NA

NACH: neoadjuvant chemotherapy, ACH: adjuvant chemotherapy, ART: adjuvant radiotherapy, NA: not available, IQR: interquartile range, CI: confidence interval.

Demographic predictors of outcomes {#s2_2}
----------------------------------

Age {#s2_3}
---

In the 29 studies about intravesical recurrence (IVR)-free survival, there was an obvious inter-study heterogeneity (*p* = 0.02); thus, the random effect model was used to pool the results. The meta-analysis showed no association between age and IVR-free survival (hazard ratio (HR), 1.01; 95% confidence interval (CI), 0.99--1.02; *p* = 0.38) (Figure [1A](#F1){ref-type="fig"}). In the 10 studies about progression free survival (PFS) there was no obvious heterogeneity among studies (*p* = 0.17; *I*^2^ = 30%); thus, the fixed effects model was used to pool the results. The pooled HR for PFS was 1.01 (95% CI, 1.01--1.02; *p* = 0.0009) (Figure [1B](#F1){ref-type="fig"}), indicating a significant association between age and PFS. A total of 27 studies were included in the analysis of cancer-specific survival (CSS). Age was associated with worse CSS (HR, 1.02; 95% CI, 1.02--1.03; *p* \< 0.00001). Since inter-study heterogeneity was not significant (*p* = 0.17; *I*^2^ = 30%), the fixed effects model was applied (Figure [1C](#F1){ref-type="fig"}). Seven studies were included in the analysis of overall survival (OS). Age was associated with worse OS (HR, 1.05; 95% CI, 1.03--1.07; *p* \< 0.00001). There was significant heterogeneity (*p* = 0.02; *I*^2^ = 61%) (Figure [1D](#F1){ref-type="fig"}).
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Gender {#s2_4}
------

Twenty-nine studies on the relationship between sex and IVR were included. The present meta-analysis indicated that female patients had a better IVR-free survival rate than male patients (HR, 0.81; 95% CI, 0.70--0.94; *p* = 0.004). However, the Cochrane *Q* test (*p* = 0.002) could not exclude a significant heterogeneity (Figure [2A](#F2){ref-type="fig"}). Nine studies provided information on PFS. There was no significant association between sex with PFS (HR, 1.06; 95% CI, 0.94--1.19; *p* = 0.33), and no heterogeneity was detected in the data (*p* = 0.96; *I*^2^ = 0%) (Figure [2B](#F2){ref-type="fig"}). A total of 27 studies evaluated the relationship between sex and CSS. The pooled HR (95% CI) of these studies for CSS was 1.04 (0.98--1.10; *p* = 0.22), and there was no heterogeneity (*p* = 0.45; *I*^2^ = 1%) (Figure [2C](#F2){ref-type="fig"}). The meta-analysis of 5 studies also demonstrated no significant association between sex and overall survival (OS) (HR, 0.95; 95% CI, 0.79--1.16; *p* = 0.63) in a fixed effects model (*p* = 0.54, *I*^2^ = 0%) (Figure [2D](#F2){ref-type="fig"}).
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Performance status {#s2_5}
------------------

Four studies were included in the analysis of the correlation between performance status and IVR-free survival. The results indicated that performance status had no relationship with IVR-free survival (HR, 1.19; 95% CI, 0.85--1.66; *p* = 0.31), and there was between-study heterogeneity (*p* = 0.03; *I*^2^ = 64%) (Figure [3A](#F3){ref-type="fig"}). The pooled analysis of PFS was based on 6 studies. No significant association between performance status and PFS was observed (pooled HR, 1.74; 95% CI, 0.92--1.65; *p* = 0.16). The test for heterogeneity recorded an *I*^2^ value of 57% (*p* = 0.04), suggesting the presence of inter-study heterogeneity (Figure [3B](#F3){ref-type="fig"}). Nine eligible studies were analyzed to evaluate the impact of performance status on CSS, and the analysis revealed that performance status was significantly related to CSS (HR, 1.35; 95% CI, 1.15--1.57; *p* = 0.0002). No significant heterogeneity was observed (*p* = 0.05; *I*^2^ = 0%) (Figure [3C](#F3){ref-type="fig"}). The pooled HR estimate for OS was 2.03 (95% CI, 0.64--6.37; *p* = 0.23) in the analysis of 2 studies, indicating no clear correlation between performance status and OS. The result for the test for heterogeneity was significant (*p* = 0.01; *I*^2^ = 85%) (Figure [3D](#F3){ref-type="fig"}).
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Smoking history {#s2_6}
---------------

Data on IVR-free survival was available from 5 studies. Smoking history was associated with a higher risk of IVR (HR, 1.38; 95% CI, 1.11--1.71; *p* = 0.003). Importantly, this analysis revealed no heterogeneity (*p* = 0.41; *I*^2^ = 0%) (Figure [4A](#F4){ref-type="fig"}). Six studies provided data on PFS. The results suggested that smoking status did not correlate with poor PFS (HR, 1.17; 95% CI, 0.79--1.73; *p* = 0.44), but there was significant heterogeneity (*I*^2^ = 59%) (Figure [4B](#F4){ref-type="fig"}). CSS rate was extracted from 7 studies. The meta-analysis indicated no significant association between smoking history and poor CSS (HR, 1.1; 95% CI, 0.89--1.37; *p* = 0.35). No significant heterogeneity was observed in the primary analysis (*p* = 0.12; *I*^2^ = 40%) (Figure [4C](#F4){ref-type="fig"}). The meta-analysis was not performed for OS because only 1 study was eligible for inclusion \[[@R10]\].
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Obesity {#s2_7}
-------

In 3 studies about IVR-free survival, the pooled HR for IVR-free survival showed that obesity was not significantly associated with IVR-free survival (HR, 1.07; 95% CI, 0.65--1.75; *p* = 0.80). However, significant heterogeneity was observed (*I*^2^ = 64%) ([Supplementary Figure 1A](#SD1){ref-type="supplementary-material"}). Of 2 studies about PFS, the pooled HR for PFS was 0.98 (95% CI, 0.47--2.06; *p* = 0.96), which suggested no significant correlation between obesity and PFS. There was no significant heterogeneity among these studies (*p* = 0.46; *I*^2^ = 0%) ([Supplementary Figure 1B](#SD1){ref-type="supplementary-material"}). Four studies reported survival analysis for CSS. Obesity was not significantly related to worse CSS (HR, 0.99; 95% CI, 0.96--1.02; *p* = 0.38). However, there was an obvious inter-study heterogeneity (*I*^2^ = 53%) ([Supplementary Figure 1C](#SD1){ref-type="supplementary-material"}). Two studies were included in the analysis of OS. Obesity did not exhibit a correlation with worse OS (HR, 0.94; 95% CI, 0.80--1.19; *p* = 0.43). The inter-study heterogeneity was significant (*I*^2^ = 51%) ([Supplementary Figure 1D](#SD1){ref-type="supplementary-material"}).

Race {#s2_8}
----

No studies were available for investigating the association between race and IVR-free survival. Furthermore, we could not perform meta-analysis for PFS and OS because only 1 study was eligible for PFS \[[@R11]\] and OS \[[@R12]\], respectively. Only 2 studies were evaluated for the impact of race on CSS. The pooled HR value was 1.02 (95% CI, 0.88--1.18; *p* = 0.79), which indicated no significant association between race and CSS. There was no heterogeneity between studies (*p* = 0.21; *I*^2^ = 37%) ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).

Publication bias {#s2_9}
----------------

Due to the small number of studies in most meta-analyses, the potential for publication bias could be reliably examined only in the meta-analyses of the correlation between age and IVR-free survival, PFS, and CSS, and between sex and IVR-free survival and CSS, which included ≥ 10 studies ([Supplementary Figures 3](#SD1){ref-type="supplementary-material"} and [4](#SD1){ref-type="supplementary-material"}). We found no strong evidence for publication bias by graphical inspection. However, Egger\'s test suggested there was a significant publication bias in the meta-analysis of the correlation between age and PFS (*p* = 0.03045). No publication bias was detected in the other meta-analyses (all *p* \> 0.05, Egger\'s test).

DISCUSSION {#s3}
==========

UTUC is a heterogeneous disease showing a variety of clinical courses. In spite of the increased detection of earlier-stage tumors resulting from the recent improvement in imaging and endoscopic techniques, UTUC still remains an aggressive disease with high recurrence and progression rates \[[@R1]\]. According to the current European Association of Urology (EAU) guidelines, the prognostic predictors of UTUC can be largely divided into preoperative clinical (demographic) and postoperative pathological factors \[[@R1], [@R2]\]. Many studies have focused mainly on pathological factors, including tumor stage, tumor grade, concomitant CIS, lymph node invasion, tumor multifocality, tumor architecture, tumor necrosis, and LVI. In contrast, the studies mainly evaluating demographic factors, such as age, sex, obesity, performance status, smoking, and race, are relatively insufficient and have shown conflicting results; therefore, the prognostic significance of demographic data has not been definitely confirmed in UTUC. However, knowledge of the prognostic significance of preoperative demographic factors is important for the counselling and management of UTUC patients.

We performed a systematic review and meta-analysis to assess whether each demographic factor could predict the survival outcomes in patients treated with RNU for UTUC. This study aggregated the outcomes of 79 studies with numbers of patients ranging from 24 to 9899. On the basis of the available data, a total of 20 meta-analyses were conducted to investigate the association of each demographic factor with survival outcomes. To the best of our knowledge, this is the first study to systematically evaluate the association between each demographic factor and postoperative survival outcomes, including IVR-free survival, PFS, CSS, and OS. Our meta-analysis found an association between survival outcomes of UTUC and demographic factors. Advanced age was significantly associated with worse PFS, CSS, and OS, but not with IVR-free survival. Male sex and smoking history only correlated with poor IVR-free survival. Performance status was exclusively related to CSS. Obesity and race did not show any association with survival outcomes.

There are several limitations for this systematic review and meta-analysis. First, because we did not use sample-size restrictions, most meta-analyses included a small number of studies (less than 10). As a result, the evaluation for publication bias was possible only in 5 meta-analyses including more than 10 studies (effect of age on IVR-free survival, PFS, and CSS, and of sex on IVR-free survival and CSS). However, among the meta-analyses assessed for publication bias, no significant bias was observed (all *p* \> 0.05 for Egger\'s test), except for the meta-analysis of the effect of age on PFS. Second, owing to scarcity or absence of data reported in the literature, the association between smoking and race and several survival outcomes (smoking and OS, race and IVR free survival, PFS, and PS) could not be evaluated in this meta-analysis. Third, there was a significant heterogeneity among studies included in half of the current meta-analyses. The meta-regression and subgroup analysis to identify the source of inter-study heterogeneity was not carried out in the present study. Although the random-effects model, which accounts for heterogeneity, was applied to analyze the studies with heterogeneity, the conclusions yielded in this systematic review and meta-analysis should be interpreted with caution \[[@R13], [@R14]\]. Fourth, the results of this systematic review and meta-analysis were partially drawn on the basis of unadjusted estimates from Kaplan-Meier or univariate Cox regression analyses because some studies did not provide detailed information. Furthermore, it should be kept in mind that a possible bias \[[@R15]\] may be due to the retrospective nature of almost all studies analyzed, except for one \[[@R9]\]. To the best of our knowledge, high quality prospectively, randomized controlled trials investigating the association between demographic factors and prognosis in UTUC have not been published to date. Finally, we cannot exclude the selection bias by including only English language written articles.

This first meta-analysis has yielded significant associations between demographic factors and IVR, progression and mortality in patients with UTUC who underwent RNU, although these findings need to be interpreted with caution. Based on a meta-analysis of the available data, age is one of the most important demographic marker, and is independently associated with mortality. We also identified male sex and smoking history as significant predictors of IVR. However, since the current evidence lacks prospective evaluation of this relationship, large, well-designed prospective studies are required to investigate the precise prognostic significance of demographic factors.

MATERIALS AND METHODS {#s4}
=====================

A systematic review was performed in accordance with Cochrane Collaboration and Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines \[[@R16]\].

Search strategy {#s4_1}
---------------

PubMed was searched for all articles published till December 2014 on the topic of interest. Search terms used were ("nephroureterectomy") and ("cancer" OR "carcinoma"). Article selection was performed by two independent evaluators (H.S.K., C.W.J.), and all the discrepancies between the two were resolved.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

According to the PRISMA guidelines, we used the Population, Intervention, Comparator, Outcome, and Study design (PICOS) approach to define study eligibility \[[@R16]\].

Population: patients with UTUC.

Intervention: RNU.

Comparator: demographic data including age, sex, performance status, smoking status, obesity, and race.

Outcome: IVR-free survival, PFS, CSS, and OS.

Study design: univariate and/or multivariate Cox regression analysis.

The inclusion criteria were: (1) original article, (2) human research, (3) English language, (4) UTUC, (5) treatment exclusively with RNU, and (6) availability of Kaplan-Meier/Cox regression-derived results for the prognostic value of demographics on UTUC outcomes according to the REMARKS guidelines for assessment of prognostic markers \[[@R17]\]. No sample-size restrictions were used. Studies using analyses other than survival analysis were not included. In addition, studies which did not offer sufficient data to acquire the hazard ratio (HR) and its standard error (SE) were excluded. If duplicate study populations or analyses of repeated data were identified, only the most recent or most complete study was preferentially assessed.

In the present meta-analysis, IVR-free survival was defined as the interval between surgery and the occurrence of UC in the bladder. PFS was defined as the interval between surgery and the subsequent appearance of local failure, either at the operative site or in the regional lymph nodes, or distant metastasis, while recurrence in the bladder was not included in PFS analysis. We excluded from PFS analysis the studies in which PFS was defined as recurrence both in bladder and non-bladder lesions. CSS and OS were defined as the interval between surgery and death from UTUC or death from any cause, respectively.

Data extraction and analysis {#s4_3}
----------------------------

Two authors (C.K. and H.H.K.) performed an independent review of 1,352 articles. A total of 1,037 articles were excluded upon examination of the titles and abstracts, while the full text of 315 articles was evaluated. In accordance with all previously mentioned inclusion criteria, a final selection of 79 articles was made \[[@R9]--[@R12], [@R18]--[@R92]\]; any discrepancies between the two evaluations were resolved. The PRISMA flow chart depicting the process for the systematic literature search and selection of the studies is shown in Figure [5](#F5){ref-type="fig"}.

![Preferred reporting items for systematic reviews and meta-analysis (PRISMA) flow chart](oncotarget-08-7464-g005){#F5}

Data was independently extracted by two authors (H.S.K. and J.H.K.) from all the included studies and subsequently crosschecked to ensure accuracy. Any discrepancies between the two authors were resolved. Information was retrieved according to the REMARKS guidelines for reporting prognostic markers, including author, country, journal, publication year, prognostic factors examined, study design, study population (sample size, recruitment period, and follow-up), patient characteristics, treatment received, statistical method applied (with variables used for adjustment), and reported impact of examined factors on UTUC outcome using univariate or multivariate analyses.

Meta- analysis {#s4_4}
--------------

We conducted a meta-analysis to summarize quantitatively the overall prognostic value of demographic factors. The cumulative effects of factors of interest were evaluated by the inverse variance method. If the 95% CI was not reported, due to the paucity of prognostic literature directly reporting these values, previously reported indirect methods were utilized to extract the log HR and variance \[[@R93]\]. Either the fixed-effects or the random-effects model was used, in case of absence or presence of between-study heterogeneity, respectively. Statistical heterogeneity was assessed using both the Cochran *Q* test and the *I*^2^ statistic, which describes the percentage of total variation across studies caused by heterogeneity rather than by chance. A value of *p* \< 0.05 for the Cochran *Q* test or an *I*^2^ statistic \> 50% indicated the presence of significant heterogeneity across selected studies \[[@R13], [@R14]\] which resulted in the use of the random-effects model based on the Der Simonian method for estimating the tau value \[[@R13]\]. To assess the risk of publication bias, we used a funnel plot and the Egger test for outcomes when at least 10 statistically significant studies were included in the meta-analysis \[[@R15]\]. The meta-analysis was performed using RevMan 5.0 statistical software (the Cochrane Collaboration, Copenhagen).
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